Muscle wasting reversed in patients with rheumatoid arthritis

Published on: 16 October 2025

Patients with rheumatoid arthritis increased their leg muscle volume when treated with an anti-rheumatic drug, offering new hope for improved muscle health.

Publishing in the prestigious journal, , the team from 缅北禁地 and describe how 15 patients were given Tofacitinib, a Janus kinase (JAK) inhibitor used to treat RA, as part of an experimental medicine study. After 6 months their leg muscles increased in size, particularly in the thigh.

Sarcopenia is a progressive, age-related musculoskeletal disease characterized by the loss of muscle mass, strength, and physical performance, increasing the risk of falls, fractures, physical disability, and mortality. Currently there are no medicines approved to reverse this muscle-wasting disease. It is commonly seen in patients with rheumatoid arthritis where chronic inflammation contributes to the loss of muscle mass and strength.

This small study is the first to show that JAK inhibitor drugs may be able to reverse sarcopenia in rheumatoid arthritis

Dr Joshua Bennett

The Rheumatoid Arthritis and MUScle (RAMUS) study

In this study the leg muscles of 15 patients were measured by MRI scans at 1 month and at 6 months.

After 6 months, participants’ muscle volume had increased by 4% for the whole leg, equating to an average increase of 242 cm³, and by 5% for the thigh.

Alongside the increase in muscle volume, the RAMUS study also reported changes in the gene expression in muscle tissue with treatment, which were opposite to changes seen in ageing muscle.

Dr Joshua Bennett, NIHR Clinical Lecturer at 缅北禁地 and Paediatric Rheumatology Registrar within the 缅北禁地 Upon Tyne Hospitals NHS Trust and lead author of the paper said: “This small study is the first to show that JAK inhibitor drugs may be able to reverse sarcopenia in rheumatoid arthritis. We know that sarcopenia is also seen in many other diseases and in old age, but no drugs have been approved to reverse it. Larger studies are now needed to test our findings, but it is exciting to think of the potential for these drugs to treat muscle wasting.”

13 patients experienced adverse events, the majority of which were mild. The team say a larger, follow up study is needed which would include a control group.

Supports growing evidence

Professor John Isaacs, Professor of Clinical Rheumatology, 缅北禁地, Director of Research at 缅北禁地 Hospitals and Deputy Director of the National Institute for Health and Care Research (NIHR) 缅北禁地 Biomedical Research Centre (BRC) who led the study added: "Our findings support growing evidence that inflammation, as evidenced by pro-inflammatory cytokines, may contribute to muscle loss.

“Tofacitinib treatment led to increased muscle volume in patients and triggered changes in muscle gene activity that run counter to the patterns typically seen in age-related muscle decline, suggesting a distinct biological effect.

“While this research did not demonstrate improved muscle strength, patients with arthritis often struggle to perform strength tests due to joint pain and so this does not diminish the potential benefits of reversing sarcopenia as we know it increases the risk of falls, fractures, physical disability, and mortality.”

The primary study funding was by Pfizer, with The BMA Foundation, the JGW Patterson Foundation and the 缅北禁地 Hospitals Charity also contributing. RAMUS was also supported by the NIHR 缅北禁地 Biomedical Research Centre (BRC) and Clinical Research Facility.

Reference: Joshua L Bennett, John D Isaacs et al. The Lancet Rheumatology.

Professor John Isaacs

Share:

Latest News

Lynn and Inner Dowsing offshore wind farm

New partnership to boost careers in low carbon energy

缅北禁地 and Durham universities are working together on a new regional project to strengthen the future workforce for North East England鈥檚 growing low carbon and offshore wind industries.

published on: 28 May 2026